530239 (3)
| Date | Circular | Tags | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BSE informs trading members that 4,477,612 new equity shares of Suven Life Sciences Ltd are listed and permitted to trade effective February … | |||||||||||||||
BSE informs trading members that 4,477,612 new equity shares of Suven Life Sciences Ltd are listed and permitted to trade effective February 26, 2026, issued on a preferential basis pursuant to conversion of warrants.
| |||||||||||||||
BSE lists 4,477,612 new equity shares of Suven Life Sciences Ltd issued on preferential basis pursuant to conversion of warrants, effective … | |||||||||||||||
BSE lists 4,477,612 new equity shares of Suven Life Sciences Ltd issued on preferential basis pursuant to conversion of warrants, effective February 26, 2026.
| |||||||||||||||
BSE lists 4,477,612 new equity shares of Suven Life Sciences Ltd issued on a preferential basis via conversion of warrants, effective … | |||||||||||||||
BSE lists 4,477,612 new equity shares of Suven Life Sciences Ltd issued on a preferential basis via conversion of warrants, effective February 26, 2026.
| |||||||||||||||